Sitagliptin, insulin combo better than insulin alone for treatment of LADA: Study

Written By :  Medha Baranwal
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2021-02-16 00:45 GMT   |   Update On 2021-02-16 00:45 GMT

China: Sitagliptin plus insulin treatment improves insulin sensitivity and maintain β-cell function in latent autoimmune diabetes in adults (LADA) compared to insulin treatment alone, finds a recent study in the Journal of Clinical Endocrinology & Metabolism.

The long-term effects of dipeptidyl peptidase-4 inhibitors on insulin sensitivity and β-cell function in LADA is not clear. Zhiguang Zhou, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China, and colleagues, therefore, aimed to investigate the effects of sitagliptin on β-cell function and insulin sensitivity in LADA patients receiving insulin.

For the purpose, the researchers performed a randomized controlled trial at the Second Xiangya Hospital. It included 51 LADA patients who were randomized to either sitagliptin + insulin group (SITA group) or insulin alone group (CONT group) for 24 months.

Fasting C-peptide (FCP), 2-hour postprandial C-peptide (2hCP) during mixed-meal tolerance test, △CP (2hCP - FCP) and updated homeostatic model assessment of β-cell function (HOMA2-B) were deterrmined every 6 months. Hyperglycemic clamp and hyperinsulinemic euglycemic clamp (HEC) tests were further conducted at 12-month intervals in 12 subjects. 

Key findings of the study include:

  • During the 24-month follow-up, there were no significant changes in β-cell function in SITA group, whereas the levels of 2hCP and △CP in CONT group were reduced at 24 months.
  • The changes in HOMA2-B from baseline were larger in SITA group than in CONT group.
  • At 24 months, first-phase insulin secretion was improved in SITA group by hyperglycemia clamp, which was higher than in CONT group, while glucose metabolized(M), insulin sensitivity index and M over logarithmical insulin ratio in HEC were increased in SITA group, which were higher than in CONT group.

"Compared with insulin intervention alone, sitagliptin plus insulin treatment appeared to maintain β-cell function and improve insulin sensitivity in LADA to some extent," concluded the authors. 

The study titled, "Islet function and insulin sensitivity in latent autoimmune diabetes in adults taking sitagliptin: A randomized trial," is published in the Journal of Clinical Endocrinology & Metabolism.

DOI: https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgab026/6105049



Tags:    
Article Source : Journal of Clinical Endocrinology & Metabolism

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News